Evidence map›Paper›PMID 12476312›Full record

ReviewOncogene2002

The basis of T-cell-mediated immunity to chronic myelogenous leukemia.

Jeffrey J Molldrem, Shreya Kant, Weidong Jiang, Sijie Lu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jeffrey J MolldremTransplantation Immunology Section, Department of Blood and Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. jmolldre@notes.dacc.tmc.edu
Shreya Kant
Weidong Jiang
Sijie Lu

Funding

IMMUNOTHERAPY OF LOW RISK MYELODYSPLASTIC SYNDROMER01CA085843 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI MOLLDREM, JEFFREY J · 2001 to 2005
$1.1M
PROTEINASE 3 SPECIFIC IMMUNOTHERAPY OF LEUKEMIAR01CA081247 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI MOLLDREM, JEFFREY J · 1999 to 2002
$532k
NCI NIH HHS CA81247NCI NIH HHS CA85843
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunity, CellularHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveT-Lymphocytes

Identifiers

PMID12476312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.